Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beam Therapeutics Inc
(NQ:
BEAM
)
23.65
-0.70 (-2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Being First Is Not Enough For Crispr Therapeutics
November 15, 2021
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.
Via
InvestorPlace
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
November 12, 2021
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
November 09, 2021
Can this high-flying gene-editing stock keep on climbing for new investors?
Via
The Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
November 08, 2021
Beam Therapeutics (NASDAQ:BEAM) brought in sales totaling $763.00 thousand during Q3 according to data provided by Benzinga Pro. However, earnings decreased 18.08%, resulting in a...
Via
Benzinga
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
October 19, 2021
Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:
Via
Benzinga
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
October 15, 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Via
The Motley Fool
Exposures
Product Safety
Beam Therapeutics Stock Flashes Renewed Technical Strength
October 12, 2021
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.
Via
Investor's Business Daily
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
September 27, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce...
Via
Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
September 23, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing. ...
Via
Benzinga
Beam Therapeutics's Return On Capital Employed Insights
September 22, 2021
According to data from Benzinga Pro, during Q2, Beam Therapeutics's (NASDAQ:BEAM) reported sales totaled $6.00 thousand. Despite a 70.57% increase in earnings, the company...
Via
Benzinga
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
September 15, 2021
The FDA has signed off Magenta Therapeutics Inc's (NASDAQ: MGTA) IND application for MGTA-117. Related Content: Magenta Therapeutics Stock Drops As FDA...
Via
Benzinga
Exposures
Product Safety
Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?
September 12, 2021
One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.
Via
The Motley Fool
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
September 03, 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Via
InvestorPlace
The 3 Best Biotech Stocks to Buy Right Now
August 27, 2021
Let your portfolio reflect your personality.
Via
The Motley Fool
3 Stocks to Avoid if Cathie Wood's ARK ETF Falls
August 21, 2021
They likely to do the worst if Michael Burry is right.
Via
The Motley Fool
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
July 16, 2021
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
Via
The Motley Fool
WHO Issues Framework For Governance For Gene Editing Technologies
July 12, 2021
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...
Via
Benzinga
A Comprehensive Guide To Genomic ETFs
July 11, 2021
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...
Via
Talk Markets
Is It Too Late to Buy Intellia Therapeutics?
July 10, 2021
After skyrocketing 68% last week, will this stock keep running higher?
Via
The Motley Fool
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
Why Beam Therapeutics Climbed 64.5% in June
July 08, 2021
A gene editing milestone sent the entire sector higher last month.
Via
The Motley Fool
61 Biggest Movers From Yesterday
July 07, 2021
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday....
Via
Benzinga
Here's What Drove Gene Editing Stocks Higher This Week
July 02, 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Via
The Motley Fool
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
July 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
July 01, 2021
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...
Via
Benzinga
Why Gene Editing Stocks Are Trading Higher Again Today
June 30, 2021
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...
Via
Benzinga
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
July 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...
Via
Benzinga
Exposures
Product Safety
72 Biggest Movers From Yesterday
July 01, 2021
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.